Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Building CAR T Facility in Philadelphia

publication date: Mar 12, 2015
WuXi PharmaTech, a China-US CRO, will build a new facility on its Philadelphia campus to manufacture viral vector cell therapy products, such as chimeric antigen receptor T cell (CAR T cell) therapies. The 145,000-square-foot cGMP plant is in addition to a 45,000 square foot cell therapy manufacturing facility WuXi announced one year ago, which is now nearing completion. WuXi said the cost for the two Philadelphia manufacturing plants totals $40 million. In China, WuXi has two additional building projects underway: a small-molecule plant in Changzhou and a commercial-scale biologics plant in Wuxi city at a total cost of $300 million. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital